M Pharmaceutical Inc.

M Pharmaceutical Inc.

March 05, 2015 08:30 ET

M Pharmaceutical Inc. Retains US Law Firm to Act as Designated Advisor

VANCOUVER, BRITISH COLUMBIA--(Marketwired - March 5, 2015) - M Pharmaceutical Inc., ( the "Company") (CSE:MQ) (OTC:PTWHF) announces that it has retained the law firm of Szaferman, Lankind, Brumstein & Blader, P.C., ("Szaferman") to act as the Company's Designated Advisor for Disclosure ("DAD") to assist in the requirements for the OTCQB marketplace. Szaferman has been recognized as one of the leading financial legal firms in the country. The Lawrenceville, N.J.-based firm was recognized in the 2014 and 2015 editions of U.S. News & World Report's Best Law Firms as a Tier-1 firm.

Gregg Jaclin, Esq, Chair of the Securities Law Practice Group at Szaferman, said "We look forward to working with M Pharmaceutical Inc. as their advisor while management executes its North American growth strategy."

George Tsafalas, Director of M Pharmaceutical Inc. stated, "In addition to our Canadian and European listings we are conscious that the US trading markets are of importance for disclosure and growth of the Company and we are pleased to work with Szaferman as our advisor through this process."

About M Pharmaceutical Inc.

The Company has closed an arms-length agreement to acquire and commercialize the rights to a biomedical device for the self-monitoring of blood glucose, primarily by diabetics. This device, called the eMosquito, is based on a novel in-plane actuator designed to provide minimally-invasive skin penetration to be used by persons with diabetes. The objective of the eMosquito is to obtain whole blood samples by penetrating the skin to shallower depths and in less sensitive areas of the body. Persons with diabetes have traditionally used the "finger prick" method to monitor/test their blood glucose levels. The blood sample was obtained by pricking the finger tip, a highly sensitive area of the body. The eMosquito is envisioned to be worn like a patch with small needles designed to puncture the skin just deep enough to draw blood without affecting the nerve endings and causing little or no pain. The commercial development of the eMosquito will require the successful coordination and execution of a wide variety of technology disciplines.


This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the commercialization of the rights to the eMosquito, including the achievement of certain milestones, and the acquisition of additional products. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and such factors as the Company failing to identify and acquire additional technologies and the failure to complete the commercialization of the eMosquito.

Contact Information